




RealRate

# PHARMACEUTICAL 2022

Arena Pharmaceuticals INC  
Rank 198 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Arena Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Arena Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 77% points. The greatest weakness of Arena Pharmaceuticals INC is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 51% points.

The company's Economic Capital Ratio, given in the ranking table, is 318%, being 43% points above the market average of 275%.

| Input Variable                              | Value in 1000 USD |
|---------------------------------------------|-------------------|
| Assets, Current                             | 569,465           |
| Cost of Goods Sold                          | 0                 |
| Intangible Assets                           | 0                 |
| Liabilities, Current                        | 66,316            |
| Liabilities, Non-Current                    | 0                 |
| Other Assets                                | 196,115           |
| Other Compr. Net Income                     | -980              |
| Other Expenses                              | 78,638            |
| Other Liabilities                           | 0                 |
| Other Net Income                            | 7,866             |
| Other Revenues                              | 54                |
| Property and Equipment                      | 19,125            |
| Research and Development                    | 419,509           |
| Selling, General and Administrative Expense | 126,206           |

| Output Variable             | Value in 1000 USD |
|-----------------------------|-------------------|
| Assets                      | 784,705           |
| Liabilities                 | 66,316            |
| Expenses                    | 624,353           |
| Revenues                    | 54                |
| Stockholders Equity         | 718,389           |
| Net Income                  | -616,433          |
| Comprehensive Net Income    | -616,923          |
| BaseVar                     | 742,137           |
| ECR before LimitedLiability | 223%              |
| Economic Capital Ratio      | 318%              |